Medpace Holdings, Inc. (NASDAQ: MEDP), a leading global provider of clinical research services, reported strong third-quarter 2024 financial results on Friday, but the company's stock plunged in after-hours trading.
For the quarter ended September 30, 2024, Medpace posted revenue of $533.3 million, an 8.3% increase from the same period last year. However, this figure narrowly missed analysts' consensus estimate of $540.5 million.
On the profitability front, the company reported net income of $96.4 million, or $3.01 per diluted share, representing a significant 36.7% year-over-year increase. This exceeded Wall Street's expectations of $2.77 per share.
Medpace's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the third quarter rose 31.7% to $118.8 million, with an EBITDA margin of 22.3%, reflecting improved operational efficiency and cost management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.